Marc Frahm
Stock Analyst at TD Cowen
(0)
# 4962
Out of 5,218 analysts
22
Total ratings
8.33%
Success rate
-34.60%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Theravance Biopharma | Maintains: Hold | 10 9 | 9.99 | -9.91% | 3 | Aug 6, 2024 | |
Incyte | Maintains: Buy | 88 80 | 69.38 | 15.31% | 3 | May 1, 2024 | |
Sana Biotechnology | Initiates Coverage On: Market Perform | n/a | n/a | n/a | 1 | Aug 14, 2023 | |
Cullinan Oncology | Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Jun 15, 2023 | |
DICE Therapeutics | Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 36 | n/a | n/a | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Nov 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 2 | Jun 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Feb 24, 2020 |